Ugur Acar1, Bekir Kucuk2, Mehmet Koray Sevinc3, Seckin Aykas3, Mesut Erdurmus2, Gungor Sobaci2. 1. Department of Ophthalmology, Faculty of Medicine, Hacettepe University, Kazakistan Caddesi 90/7 Emek-Ankara, Ankara, Turkey. druguracar@gmail.com. 2. Department of Ophthalmology, Faculty of Medicine, Hacettepe University, Kazakistan Caddesi 90/7 Emek-Ankara, Ankara, Turkey. 3. Department of Ophthalmology, Gulhane Military Medical Academy, Ankara, Turkey.
Abstract
AIM: To evaluate the whether intravitreal erythropoietin (EPO) administration has any beneficial or adverse effect in patients with late-stage optic neuropathy (ON) or not. METHODS: The study examined 16 eyes of 16 patients who had late-stage ON and ≥1/20 best-corrected visual acuity (BCVA) in their affected eye. There were nonarteritic ischemic ON in 10 (62.5%) eyes, traumatic ON in 4 (25.0%) eyes and methanol-induced ON in 2 (12.5%) eyes. Using pars plana approach, 2000 IU/0.2 ml EPO was administered intravitreally with a 30-gauge needle. Injections were administered three times with 6-week intervals. We compared the differences in the BCVA, intraocular pressure (IOP), retinal nerve fiber layer (RNFL) thickness, pattern visual evoked potentials (p-VEP) and pattern electroretinography (p-ERG) parameters performed at initial examination and final visits. RESULTS: The mean age of the patients was 52.38 ± 12.00 years; 2 (12.50%) of them were female, and 14 (87.50%) of them were male. The mean BCVA levels of 16 patients with optic atrophy were 1.12 ± 0.25 logMAR at the initial examination and 1.08 ± 0.26 logMAR at the final visit (p = 0.102). There was no statistically significant difference between the initial and final RNFL thicknesses, IOP values, p-ERG or p-VEP responses. CONCLUSIONS: Intravitreal EPO injections have no beneficial or detrimental effect on the late stage of ON. Further studies are necessary to compare our results in patients with ON in earlier stages.
AIM: To evaluate the whether intravitreal erythropoietin (EPO) administration has any beneficial or adverse effect in patients with late-stage optic neuropathy (ON) or not. METHODS: The study examined 16 eyes of 16 patients who had late-stage ON and ≥1/20 best-corrected visual acuity (BCVA) in their affected eye. There were nonarteritic ischemic ON in 10 (62.5%) eyes, traumatic ON in 4 (25.0%) eyes and methanol-induced ON in 2 (12.5%) eyes. Using pars plana approach, 2000 IU/0.2 ml EPO was administered intravitreally with a 30-gauge needle. Injections were administered three times with 6-week intervals. We compared the differences in the BCVA, intraocular pressure (IOP), retinal nerve fiber layer (RNFL) thickness, pattern visual evoked potentials (p-VEP) and pattern electroretinography (p-ERG) parameters performed at initial examination and final visits. RESULTS: The mean age of the patients was 52.38 ± 12.00 years; 2 (12.50%) of them were female, and 14 (87.50%) of them were male. The mean BCVA levels of 16 patients with optic atrophy were 1.12 ± 0.25 logMAR at the initial examination and 1.08 ± 0.26 logMAR at the final visit (p = 0.102). There was no statistically significant difference between the initial and final RNFL thicknesses, IOP values, p-ERG or p-VEP responses. CONCLUSIONS: Intravitreal EPO injections have no beneficial or detrimental effect on the late stage of ON. Further studies are necessary to compare our results in patients with ON in earlier stages.
Authors: Kurt-Wolfram Sühs; Katharina Hein; Muriel B Sättler; Anke Görlitz; Christoph Ciupka; Kerstin Scholz; Barbara Käsmann-Kellner; Panagiotis Papanagiotou; Nina Schäffler; Cordula Restemeyer; Diana Bittersohl; Andrea Hassenstein; Berthold Seitz; Wolfgang Reith; Klaus Fassbender; Reinhard Hilgers; Christoph Heesen; Mathias Bähr; Ricarda Diem Journal: Ann Neurol Date: 2012-08 Impact factor: 10.422
Authors: Jacek Baj; Alicja Forma; Joanna Kobak; Magdalena Tyczyńska; Iga Dudek; Amr Maani; Grzegorz Teresiński; Grzegorz Buszewicz; Jacek Januszewski; Jolanta Flieger Journal: Int J Environ Res Public Health Date: 2022-03-06 Impact factor: 3.390